Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer-Reference-Cited by-同舟云学术

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer

Published:2018-05 Issue:5 Volume:33 Page:853-861.e4
ISSN:1535-6108
Container-title:Cancer Cell
language:en
Short-container-title:Cancer Cell

Author:

Hellmann Matthew D.,Callahan Margaret K.,Awad Mark M.,Calvo Emiliano,Ascierto Paolo A.,Atmaca Akin,Rizvi Naiyer A.,Hirsch Fred R.,Selvaggi Giovanni,Szustakowski Joseph D.,Sasson Ariella,Golhar Ryan,Vitazka Patrik,Chang Han,Geese William J.,Antonia Scott J.

Funder

ONO Pharmaceutical Company, Ltd.

Publisher

Elsevier BV

Subject

Cancer Research,Cell Biology,Oncology

Reference33 articles.

1. Signatures of mutational processes in human cancer;Alexandrov;Nature,2013

2. Treatment for small cell lung cancer, where are we now?—a review;Alvarado-Luna;Transl. Lung Cancer Res.,2016

3. Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial;Antonia;Lancet Oncol.,2016

4. The COSMIC (catalogue of somatic mutations in cancer) database and website;Bamford;Br. J. Cancer,2004

5. Small cell lung cancer: where do we go from here?;Byers;Cancer,2015

Cited by 693 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advances in predictive biomarkers associated with immunotherapy in extensive-stage small cell lung cancer;Cell & Bioscience;2024-09-12

2. Plasma proteome-based test (PROphetNSCLC) predicts response to immune checkpoint inhibitors (ICI) independent of tumor programmed death-ligand 1(PD-L1) expression and tumor mutational burden (TMB);2024-09-11

3. Dissecting transcriptome signals of anti-PD-1 response in lung adenocarcinoma;Scientific Reports;2024-09-10

4. Single-cell and spatial proteo-transcriptomic profiling reveals immune infiltration heterogeneity associated with neuroendocrine features in small cell lung cancer;Cell Discovery;2024-09-04

5. Adebrelimab plus chemotherapy and sequential thoracic radiotherapy as first-line therapy for extensive-stage small–cell lung cancer (ES-SCLC): a phase II trial;eClinicalMedicine;2024-09